KCNG3 (Potassium Voltage-Gated Channel Modulator Subfamily G Member 3) encodes the Kv6.3 subunit, a modulatory protein that plays critical roles in regulating neuronal potassium channel function. This gene is expressed predominantly in the brain, particularly in regions associated with learning and memory, and has been implicated in various neurological and neurodegenerative conditions.
KCNG3 encodes the Kv6.3 (KCNG3) potassium channel subunit, which functions as a regulatory subunit that modulates the activity of voltage-gated potassium (Kv) channels. Unlike pore-forming subunits, Kv6.3 does not form functional channels on its own but assembles with other Kv subunits to create heteromeric channels with unique biophysical properties.
| Property | Value |
|---|---|
| Gene Symbol | KCNG3 |
| Full Name | Potassium Voltage-Gated Channel Modulator Subfamily G Member 3 |
| Chromosomal Location | 2p25.2 |
| NCBI Gene ID | 170302 |
| Ensembl ID | ENSG00000171056 |
| UniProt ID | Q9Y667 |
| RefSeq mRNA | NM_001172206 |
| Protein Length | 436 amino acids |
The KCNG3 protein contains several key structural features:
KCNG3 plays a crucial role in regulating neuronal excitability through its modulation of Kv channels:
KCNG3 exhibits region-specific expression in the brain:
KCNG3 may play a role in Alzheimer's disease through several mechanisms:
In Parkinson's disease, KCNG3 may be affected through:
KCNG3 mutations have been associated with epilepsy:
KCNG3 and related Kv channels represent potential therapeutic targets:
KCNG3 expression may serve as a biomarker for:
KCNG3 interacts with multiple proteins:
The study of Kcng3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev. 2000;52(4):557-594. PMID:10893102.
Wei AD, Gutman GA, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev. 2005;57(4):473-492. PMID:16382103.
Ottosson NE, Wu CL, Xue Y, et al. The voltage-gated potassium channel subfamily G family and its modulation of neuronal excitability. J Neurochem. 2024;168(5):812-829. doi:10.1111/jnc.16045.
Guan D, Armstrong WE, Foehring RC. Kv2 channels and neuronal excitability in health and disease. Neuropharmacology. 2023;228:109445. doi:10.1016/j.neuropharm.2023.109445.
Huang Y, Tu L, Chen J, et al. Potassium channel dysfunction in Alzheimer's disease. J Alzheimers Dis. 2022;85(1):41-56. doi:10.3233/JAD-215432.
Zhang Y, Li M, Chen Q, et al. The role of voltage-gated potassium channels in Parkinson's disease. Mov Disord. 2021;36(9):2028-2042. doi:10.1002/mds.28654.
Pongs O, Schwarz JR. Ancillary subunits associated with voltage-dependent K+ channels. Physiol Rev. 2010;90(2):755-796. PMID:20393197.
Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev. 2008;88(4):1407-1447. PMID:18923186.